Ángel Arturo LÓPEZ-GONZÁLEZ, Zoe MANZANERO, María Teófila VICENTE-HERRERO, Sheila GARCÍA-AGUDO, María GIL-LLINÁS, Francisco MORENO-MORCILLO

Relationship between blood glucose levels and cardiovascular risk in the Spanish Mediterranean population

Background/aim: Diabetes is associated with an increased prevalence of cardiovascular disease. Impaired fasting glucose (IFG) is an intermediate clinical situation between normal glucose levels and type 2 diabetes. The aim of this study is to determine how fasting glucose concentrations affect different cardiovascular risk scales. Materials and methods: A descriptive study was conducted with 59,041 Mediterranean Spanish workers. IFG was determined using the American Diabetes Association (ADA) and the World Health Organization (WHO) criteria. Different indicators of cardiovascular risk were analyzed: body mass index, waist circumference, waist-to-height ratio, blood pressure, lipid parameters, atherogenic indices, metabolic syndrome, and various scales of cardiovascular risk such as REGICOR, DORICA, SCORE, Heart Age, and Vascular Age. Results: All cardiovascular scales showed statistically significant differences between the IFG group and the normal glucose group. In all cases, values were worse in the IFG group; furthermore, men exhibited more unfavorable levels of cardiovascular risk factors than women. Higher odds ratio values were present in employees with metabolic syndrome according to ATP III criteria (9.42, 95% CI: 8.56 10.37 using WHO criteria and 9.25, 95% CI: 8.67 9.87 using ADA criteria). Conclusions: IFG increases cardiovascular risk whether using classical scales (REGICOR, SCORE, and metabolic syndrome) or other less studied scales (atherogenic indices, Heart Age, and Vascular Age).

PDF

___

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37: S81-90.
2. Lee M, Saver JL, Hong KS, Chang KH, Ovbiagele B. Effect of pre-diabetes on future risk of stroke: meta-analysis. BMJ 2102; 344: e3564.
3. NICE. Preventing Type 2 Diabetes: Risk Identification and Interventions for Individuals at High Risk. NICE Public Health Guidance 38, Issued July 2012. London, UK: NICE; 2012.
4. Paulweber B, Valensi P, Lindström J, Lalic NM, Greaves CJ, McKee M, Kissimova-Skarbek K, Liatis S, Cosson E, Szendroedi J et al. A European evidence based guideline for the prevention type 2 diabetes. Horm Metab Res 2010; 42: S3-36.
5. [No authors listed.] Bioelectrical impedance analysis in body composition measurement: National Institutes of Health Technology Assessment Conference Statement. Am J Clin Nutr 1994; 64: 524S-532S.
6. WHO. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. Geneva, Switzerland: WHO; 2000.
7. Ramos R, Solanas P, Cordón F, Rohlfs I, Elosua R, Sala J, Masiá R, Faixedas MT, Marrugat J. Comparación de la función de Framingham original y la calibrada de REGICOR en la predicción del riesgo coronario poblacional. Med Clin (Barc) 2003; 121: 521-526 (in Spanish).
8. Marrugat J, Subirana I, Comín E, Cabezas C, Vila J, Elosua R, Nam BH, Ramos R, Sala J, Solanas P et al. Validity of an adaptation of the Framingham cardiovascular risk function; the VERIFICA Study. J Epidemiol Community Health 2007; 61: 40-47.
9. Marrugat J, Vila J, Baena-Díez JM, Grau M, Sala J, Ramos R, Subirana I, Fitó M, Elosua R. Validez relativa de la estimación del riesgo cardiovascular a 10 años en una cohorte poblacional del estudio REGICOR. Rev Esp Cardiol 2011; 64: 385-394 (in Spanish).
10. Aranceta J, Pérez Rodrigo C, Foz Sala M, Mantilla T, Serra Majem L, Moreno B, Monereo S, Millán J. Tablas de evaluación del riesgo coronario adaptadas a la población española. Estudio DORICA. Med Clin (Barc) 2004; 123: 686-691 (in Spanish).
11. Sans S, Fitzgerald AP, Royo D, Conroy D, Graham I. Calibración de la tabla SCORE de riesgo cardiovascular para España. Rev Esp Cardiol 2007; 60: 476-485 (in Spanish).
12. DAgostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation 2008; 117: 743-753.
13. Lopez-Gonzalez AA, Aguilo A, Frontera M, Bennasar-Veny M, Campos I, Vicente-Herrero T, Tomas-Salva M, De PedroGomez J, Tauler P. Effectiveness of the Heart Age tool for improving modifiable cardiovascular risk factors in a Southern European population: a randomized trial. Eur J Prev Cardiol 2015; 22: 389-396.
14. Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE Project scales: a new method of cardiovascular risk evaluation. Eur Heart J 2010; 31: 2351- 2358.
15. Orgaz-Morales MT, Hijano-Villegas S, Martínez-Llamas MS, López-Barba J, Diáz-Portillo J. Guía del paciente con trastornos lipídicos. Madrid, Spain: Ministerio de Sanidad y Consumo, Instituto Nacional de Gestión Sanitaria; 2007 (in Spanish).
16. Díaz-Redondo A, Giráldez-García C, Carrillo L, Serrano R, García-Soidán FJ, Artola S, Franch J, Díez J, Ezkurra P, Millaruelo JM. Modifiable risk factors associated with prediabetes in men and women: a cross-sectional analysis of the cohort study in primary health care on the evolution of patients with prediabetes (PREDAPS-Study). BMC Family Practice 2015; 16: 5.
17. Kim HK, Kim CH, Kim EH, Bae SJ, Choe J, Park JY, Park SW, Yun YD, Baek SJ, Mok Y et al. Impaired fasting glucose and risk of cardiovascular disease in Korean men and women. Diabetes Care 2013; 36: 328-335.
18. Qiu M, Shen W, Song X, Ju L, Tong W, Wang H, Zheng S, Jin Y, Wu Y, Wang W et al. Effects of prediabetes mellitus alone or plus hypertension on subsequent occurrence of cardiovascular disease and diabetes mellitus: longitudinal study. Hypertension 2015; 65: 525-530.
19. Malaga G, Zevallos-Palacios C, Lazo MA, Huayanay C. Elevada frecuencia de dislipemia y glucemia basal alterada en una población peruana de altura. Rev Per Med Exp Salud Publica 2010; 27: 557-561 (in Spanish).
20. López-González AA, Rivero Y, Vicente-Herrero MT, Queimadelos M, Monroy MN, Núñez C. Influencia del consumo de tabaco, actividad física, alimentación y edad en los valores de diferentes índices aterogénicos en población mediterránea española. Medicina Balear 2014; 29: 23-31 (in Spanish).
21. López-González AA, Rivero Y, Vicente-Herrero MT, Gíl M, Tomás-Salvá M, Riutord B. Índices aterogénicos en trabajadores de diferentes sectores laborales del área mediterránea española. Clin Investig Arterioscler 2015; 27: 118-128 (in Spanish).
22. Leguen-Gulgar LL, Castellanos M, Sanchez-Bouza MJ, BenetRodriguez M. Factores de riesgo cardiovasculares y su relación con las alteraciones del metabolismo de los glúcidos y lípidos. Revista Finlay 2014; 4: 1-12 (in Spanish).
23. Ford ES, Guixiang Z, Chaoyang L. Pre-diabetes and the risk for cardiovascular disease. J Am Coll Cardiol 2014; 55: 1310-1317.
24. Perreault L, Temprosa M, Mather KJ, Horton E, Kitabchi A, Larkin M, Montez MG, Thayer D, Orchard TJ, Hamman RF et al. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program Outcomes Study. Diabetes Care 2014; 37: 2622-2631.